NCT04560179View on ClinicalTrials.gov

Inhaled Tobramycin in BPD

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

May 17, 2024

Conditions
Bronchopulmonary Dysplasia
Interventions
DRUG

Tobramycin solution for inhalation 78mg dose

Inhaled tobramycin - 78mg administered every 12 hours for 14 days.

DRUG

Tobramycin solution for inhalation 150mg dose

Inhaled tobramycin - 150mg administered every 12 hours for 14 days.

DRUG

Tobramycin solution for inhalation 216mg dose

Inhaled tobramycin - 216mg administered every 12 hours for 14 days.

DRUG

Tobramycin solution for inhalation 300mg dose

Inhaled tobramycin - 300mg administered every 12 hours for 14 days.

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

University of Florida

OTHER

lead

Erik Allen Jensen

OTHER